Jefferies stays Buy on Erasca Inc (ERAS): ASCO'26 a potential inflection point with Ph1 monotx data presentation likely

Jefferies analyst Maury Raycroft reiterated a Buy rating and $21.00 price target on Erasca Inc (NASDAQ: ERAS)

The analyst commented, "We see ASCO’26 as a pot'l inflection point for ERAS, w/ ’0015’s initial ph.I monotx data likely presented there. That readout will test whether ERAS can match/beat RVMD on efficacy while differentiating on combinability (better rash/GI/stomatitis + linear PK). With early low-dose activity and preclin potency/PK edges, we believe even modest early separation should drive a (+)ve stock reaction as investors look through RVMD’s $30B+ takeout chatter."

For an analyst ratings summary and ratings history on Erasca Inc click here. For more ratings news on Erasca Inc click here.

Shares of Erasca Inc closed at $19.01 yesterday.

You May Also Be Interested In

• Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
• Freedom Broker Upgrades Procter & Gamble (PG) to Buy
• FDA approves first once-weekly insulin for type 2 diabetes mellitus in pediatric patients